Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations
Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
Final long-term overall survival data from APHINITY confirm the efficacy of dual HER2 blockade in patients with node-positive disease
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
A timing window for testing ESR1 mutations in the blood was identified
Defining patients most likely to respond, a better understanding of the host–tumour immune axis and clinical trials for specific subtypes are key to extending success
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes
ESMO continues its commitment to gender-diverse and sex-specific oncology to address the growing need to close knowledge gaps among oncologists
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.